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Selective serotonin reuptake inhibitors (SSRIs) are a widely prescribed class of antide-
pressants. Laboratory and epidemiologic evidence suggests that a prolactin-mediated
mechanism secondary to increased serotonin levels at neuronal synapses could lead to
a potentially carcinogenic effect of SSRIs. In this population-based case-control study, we
evaluated the association between SSRI use and breast cancer risk as a function of their
relative degree of inhibition of serotonin reuptake as a proxy for their impact on prolactin
levels. Cases were 2,129 women with primary invasive breast cancer diagnosed from
2003 to 2007, and controls were 21,297 women randomly selected from the population
registry. Detailed information for each SSRI prescription dispensed was compiled using the
Saskatchewan prescription database. Logistic regression was used to evaluate the impact
of use of high and lower inhibitors of serotonin reuptake and duration of use, as well as to
assess the effect of individual high inhibitors on the risk of breast cancer. Exclusive users of
high or lower inhibitors of serotonin reuptake were not at increased risk for breast cancer
compared with non-users of SSRIs (OR=1.01, CI=0.88–1.17 and OR=0.91, CI=0.67–
1.25 respectively), regardless of their duration of use or menopausal status. While we
cannot rule out the possibility of a clinically important risk increase (OR=1.83, CI=0.99–
3.40) for long-term users of sertraline (≥24 prescriptions), given the small number of
exposed cases (n=12), the borderline statistical significance, and the wide confidence
interval, these results need to be interpreted cautiously. In this large population-based case-
control study, we found no conclusive evidence of breast cancer risk associated with the
use of SSRIs even after assessing the degree of serotonin reuptake inhibition and duration
of use. Our results do not support the serotonin-mediated pathway for the prolactin-breast
cancer hypothesis.
Keywords: selective serotonin reuptake inhibitors, SSRIs, breast cancer, prolactin, antidepressants, case-control
studies
INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are prescribed
widely for the treatment of depression as well as for the man-
agement of chronic pain, menopausal symptoms, and migraine
headache prophylaxis (Bahl et al., 2003; Stone et al., 2003; McIntyre
et al., 2005) with prevalence estimates of SSRI use ranging from 5–
10% (Patten et al., 2005; Paulose-Ram et al., 2007). SSRIs produce
their therapeutic action and adverse effects by selectively bind-
ing to the serotonin (5-hydroxytryptamine, 5-HT) transporter,
thereby blocking the reuptake of serotonin into pre-synaptic neu-
rons, which results in enhanced serotonergic function in the brain
(Richelson, 2001; Ward and Azzaro, 2004). Using radioligand
assays, the serotonin transporter binding potency of individual
SSRIs can be classified on the basis of an agent’s dissociation con-
stant (Kd) (Tatsumi et al., 1997; Meijer et al., 2004). A lower
dissociation constant reflects a higher affinity for the serotonin
transporter which is associated with higher inhibition of serotonin
reuptake and therefore more elevated extracellular serotonin levels
at pre-synaptic junctions (Tatsumi et al., 1997; Meijer et al., 2004).
Of the SSRI antidepressants, paroxetine, sertraline, and fluoxetine
are the three most potent (high) inhibitors of serotonin reuptake,
while citalopram and fluvoxamine can be classified as relatively
lower inhibitors (Tatsumi et al., 1997; van Walraven et al., 2001;
Meijer et al., 2004; Turner et al., 2007).
In vitro and in vivo evidence suggests that serotonin modulates
prolactin production by inducing the release of prolactin releas-
ing factors (PRFs), such as vasoactive intestinal peptide (VIP)
and oxytocin (OT), from the hypothalamus. In turn, these sub-
stances stimulate lactotrophs in the pituitary gland to release
prolactin (Emiliano and Fudge, 2004). Though results are con-
flicting, several case reports and small uncontrolled studies that
assessed changes in prolactin levels with oral and intravenous SSRI
administration indicate that all SSRIs have the potential to cause
varying increases in circulating basal prolactin to levels within
and above the accepted normal range (Emiliano and Fudge, 2004;
Molitch, 2005; Coker and Taylor, 2010; Madhusoodanan et al.,
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2010; Trenque et al., 2011). The serotonin-mediated pathway has
been postulated as one mechanism to explain these observations
(Emiliano and Fudge, 2004).
There is considerable animal and in vitro laboratory evidence to
provide a biologic basis for an association between elevated pro-
lactin levels and breast cancer development in humans (Welsch
and Nagasawa, 1977; Kiss et al., 1987; Vonderhaar, 1999; Emil-
iano and Fudge, 2004; Harvey, 2005). For example, prolactin,
as a tumor-promoter, has been shown to stimulate prolifera-
tive activity in the mammary gland, suppress apoptosis (normal
process of cell self-destruction), and upregulate the BRCA1 (breast
cancer 1) gene (Vonderhaar, 1999; Harvey, 2005). In addition,
studies in humans also support an association between elevated
prolactin levels and the subsequent development of breast can-
cer. A pooled analysis of three large prospective cohort studies
reported a small increased risk for breast cancer in women with
high normal or above normal levels of prolactin (>17.6 ng/mL)
compared to women with below normal levels (≤9.8 ng/mL)
(RR= 1.3, CI= 1.1–1.6, p-trend= 0.002) (Tworoger et al., 2007).
The association was even stronger after correction for the repro-
ducibility of prolactin measurements (RR= 1.7; CI= 1.2–2.3) and
was independent of menopausal status (p for interaction= 0.95)
(Tworoger et al., 2007).
Tworoger and Hankinson (2008) concluded that accumulat-
ing evidence suggests that prolactin plays an etiologic role in
breast cancer development and recommended further assessment
of breast cancer risk associated with long-term use of medications
such as SSRIs that are known to influence circulating levels of
prolactin. Further, a recently published meta-analysis by Cosgrove
et al. (2011) reported a slight increase in the risk of breast/ovarian
cancer with the use of antidepressants (OR= 1.11, CI= 1.03–
1.20) and specifically SSRI use (OR= 1.07, CI= 0.99–1.51). In
light of these findings, Cosgrove et al. (2011) recommended fur-
ther research to examine how complex inter-relationships between
serotonin, SSRIs and prolactin may impact on breast cancer risk.
In addition, despite significant limitations of this meta-analysis
including differences between studies in terms of exposure assess-
ment, cancer sites and adjustment for potentially confounding
factors, these results have renewed public health concerns about
the potential risks associated with the use of SSRIs (Cosgrove et al.,
2011).
Given the widespread use of SSRI antidepressants especially
among women, further assessment of this biologically plausi-
ble association with breast cancer risk is warranted. In this
population-based case-control study we evaluated the effects of
SSRI use on breast cancer risk as a function of their relative degree
of inhibition of serotonin reuptake, a proxy for their impact on
prolactin levels, and their duration of use, as well as the potentially
risk-modifying effects of menopausal status.
MATERIALS AND METHODS
DATA SOURCES AND LINKAGES
Three administrative health databases from the province of
Saskatchewan (SK), Canada were linked to conduct this study:
(1) the population registry for socio-demographic information
and dates of insurance coverage; (2) the Saskatchewan prescrip-
tion drug plan database for outpatient prescriptions filled since
the mid-1970s that are eligible for coverage by the drug plan for
all Saskatchewan residents with the exception of approximately
9% of the population (primarily registered Indians); and, (3) the
Saskatchewan Cancer Agency (SCA) cancer registry database for
detailed information on cancer diagnoses since 1970 (Downey
et al., 2005). These databases are generated by the province’s uni-
versal health insurance programs where information is available
from all three databases for approximately 91% of residents (about
1 million people). Each resident is represented by a unique iden-
tifier (Health Services Number) that enables record linkage across
databases over time at the level of the individual (Downey et al.,
2005).
SELECTION OF CASES AND CONTROLS
The selection procedures for cases and controls have been
described in detail elsewhere (Ashbury et al., 2010). In brief, the
underlying study population was conceptualized as all women eli-
gible for outpatient prescription drug benefits who, during the case
accrual period of 2003–2007, were: (1) aged 28–79, (2) had pre-
scription coverage for 10 or more consecutive years prior to their
index date, and (3) had no previous cancer diagnosis in the 10 years
preceding their index date, with the exception of non-melanoma
skin cancer and in situ cervical cancer. All incident cases of pri-
mary invasive breast cancer, diagnosed between January 1, 2003
and December 31, 2007 who met these eligibility criteria were
included. Ten controls per case frequency-matched on the cases’
age in 5-year groups were selected from the underlying study pop-
ulation using an incidence density (risk-set) sampling approach
(Rothman et al., 2008). The index date for cases was the date of
breast cancer diagnosis, and for controls was defined by a randomly
chosen date corresponding to each 6-month sampling period.
We identified 2,130 women diagnosed with breast cancer [2,119
(99.5%) primary invasive cancers and 11 (0.5%) carcinomas
in situ, which were retained in the analysis because of their small
numbers], and 21,300 controls. Due to missing demographic data,
one case and three controls were excluded leaving 2,129 cases and
21,297 controls for this analysis.
SSRI USE
For each case and control, we obtained detailed information for
each SSRI prescription dispensed between either the start of their
drug plan coverage or July 1, 1989 (when the first SSRI was listed
on the SK Formulary), whichever was later, and their index date.
Information available included drug name, strength, quantity dis-
pensed, and dispensing date but did not include dosage prescribed
(number of pills per dose and total number of doses per day),
duration of the prescription, and indication for the SSRI prescrip-
tion. SSRIs covered by the provincial drug plan during the study
period and available without prescribing restrictions included
citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline.
SSRI use within a 2-year period preceding the index date was not
considered to be causally associated with breast cancer develop-
ment and therefore excluded from the analysis. This 2-year latency
period between SSRI use and breast cancer diagnosis is supported
by mathematical models of tumor growth by Moolgavkar et al.
(1980) and postulated tumor-promoter effects of SSRIs on breast
tumor growth in laboratory animals (Brandes et al., 1992). Further,
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exclusion of this 2-year SSRI exposure period prior to diagnosis
was chosen to minimize reverse causality bias (when SSRI use is
associated with growth of an existing breast malignancy that is not
yet clinically detectable).
Paroxetine, sertraline, and fluoxetine were classified as “high”
inhibitors based on their greater serotonin transporter binding
potency relative to citalopram and fluvoxamine (so-called “lower”
inhibitors) (Tatsumi et al., 1997; Richelson, 2001). In order to
test our prolactin-breast cancer hypothesis, we examined the
effects of high inhibitors independent of use of lower inhibitors.
Therefore, SSRI users were divided into three main exposure
categories: (1) exclusive users of high inhibitors (paroxetine, ser-
traline, and/or fluoxetine), (2) exclusive users of lower inhibitors
(citalopram and/or fluvoxamine), and (3) users of both high and
lower inhibitors (combined users). The comparator group for each
analysis was women with no SSRI prescriptions dispensed dur-
ing the same time period of two or more years preceding the
index date.
The duration of SSRI use analysis was based on the total num-
ber of prescriptions dispensed during the etiologically relevant
exposure time window of two or more years prior to index date
given that the exact duration of individual prescriptions was not
available. However, since SSRI prescriptions in Saskatchewan are
typically dispensed to accommodate a 34-day treatment period,
the total number of prescriptions dispensed approximated the
number of months exposed. To evaluate the effect of duration
of SSRI use on breast cancer risk, exclusive users of high and lower
inhibitors were further subdivided into two clinically relevant
exposure categories – recipients of 1–23 and ≥24 prescriptions.
These cut-offs were chosen for several reasons. Firstly, for a car-
cinogenic hypothesis, it is important to define exposure in terms
of long-term use, preferably years of use, as short durations are
unlikely to have an important effect on breast cancer risk (Shapiro,
1989). Secondly, for the main analysis (i.e., exclusive users of high
inhibitors versus non-users) our goal was to assess dose response
according to the longest duration of SSRI use possible while still
ensuring that the uppermost category of SSRI users included an
adequate number of subjects. For users of both high and lower
inhibitors (combined users), the duration cut-offs (1–23 and≥24
prescriptions) were based on the total number of prescriptions for
high inhibitors only.
We also assessed the risk for breast cancer associated with the
use of individual high inhibitors. This analysis was restricted to
persons who had used a single high inhibitor antidepressant agent
exclusively during the study period.
POTENTIAL CONFOUNDERS
Cases and controls were categorized on the basis of their age (con-
tinuous), marital status (married, single, other), place of residence
status (urban, rural), and income support status (no support, low
support, and high support) using yearly demographic data avail-
able (see Table 1 footnotes for details). Information related to oral
contraceptive and hormone therapy use was obtained from the
prescription database.
Since breast cancer is a heterogeneous disease where
menopausal status at diagnosis has been shown to reflect different
etiologies and risk factor profiles, it is plausible that prolonged
elevated levels of prolactin may affect pre- and post-menopausal
breast tissue differently (Tworoger et al., 2006). We used age at
index date (breast cancer diagnosis date for cases) as a proxy for
determining menopausal status since the latter was not available
from the data sources. Pre- and post-menopausal were defined
as <55 and ≥55 years of age, respectively. Phipps et al. (2010)
reported minimal differences in breast cancer incidence and detec-
tion rates when comparing the impact of simple age-based defi-
nitions of menopausal status (age 50 and age 55 as cut-offs) with
complex multivariable definitions thereby providing support for
the use of age as a proxy for menopausal status. In our study,
age 55 was chosen as a cut-off to avoid misclassification of pre-
menopausal cases as post-menopausal, since breast cancer cases
are more likely to self-report a later age at menopause (Morabia
and Flandre, 1992; Phipps et al., 2010). In addition, previous stud-
ies investigating the role of menopausal status on breast cancer
risk have used similar age cut-offs to define menopausal status
(Van Hoften et al., 2000; Tryggvadottir et al., 2002; Gonzalez-Perez
and Garcia Rodriguez, 2005).
STATISTICAL ANALYSIS
Logistic regression was used to evaluate the impact of use of high
and lower inhibitors of serotonin reuptake (SSRIs) and duration
of use, as well as to assess the effect of individual high inhibitors
on the risk of breast cancer using non-users of SSRIs as the com-
parator group for all analyses. To evaluate potential confounders,
the “change in estimate” method was used with covariates retained
in the final model if they changed the main exposure estimate by
10% or more (Greenland, 1989; Budtz-Jorgensen et al., 2007). No
variable (age, marital status, place of residence, income support
status, oral contraceptive, and hormone therapy use) met the defi-
nition of a confounder. However, we report risk estimates adjusted
for all of these variables since there was no loss of precision com-
pared to the parsimonious model. A two-sided test of interaction
was used with a significance threshold of α= 0.05 to test the mod-
ifying effect of age at index date (a proxy for menopausal status)
(Altman and Bland, 2003).
SENSITIVITY ANALYSIS
As non-compliance is a potential source of exposure misclassifica-
tion, we repeated all analyses changing the referent category from
no prescriptions to ≤1 prescription.
RESULTS
The study population consisted of 2,129 cases and 21,297 con-
trols. Among the cases, approximately 75% had infiltrating ductal
carcinoma, 10% lobular carcinoma, and 15% had a mix of other
morphologies. Almost 44% (43.8%) presented as stage one, 36.2%
stage two, 13.0% stage three, 4.6% stage four, 0.5% in situ, and for
1.9%, stage could not be assessed. The proportion of breast cancer
cases diagnosed each year was similar across the 5-year accrual
period.
Cases and controls were similar with regard to age, duration of
follow-up, receipt of income support (a marker of socio-economic
status), and place of residence (Table 1). However, cases were
somewhat more likely to be married and to have been heavy users
of oral contraceptives and/or hormone therapy than controls.
These differences were controlled for in the analysis.
Table 2 shows the unadjusted and adjusted ORs and 95% con-
fidence intervals for breast cancer risk according to the degree
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Table 1 | Characteristics of breast cancer cases and age-matched controls.
Characteristic Cases
N =2129
(%) Controls
N =21297
(%) Unadjusted ORa
n n (95% CI)
Age (years)
Mean (SD) 60.4 (11.4) 60.3 (11.4)
Age categories
<40 57 (2.7) 570 (2.7) 1.00 (Reference)
40–55 685 (32.2) 6972 (32.7) 0.98 (0.74, 1.31)
>55 1387 (65.2) 13755 (64.6) 1.01 (0.76, 1.33)
Follow-up (years)b
Mean (SD) 28.9 (3.5) 28.8 (3.7) 1.01 (0.99, 1.02)
Median (range) 30.0 (10, 32) 30.0 (10.32)
Marital statusc
Other (widowed, separated, divorced) 393 (18.5) 4386 (20.6) 1.00 (Reference)
Single 139 (6.5) 1421 (6.7) 1.09 (0.89, 1.34)
Married 1597 (75.0) 15490 (72.7) 1.15 (1.03, 1.29)
Income support statusd
No income support 1542 (72.4) 15049 (70.7) 1.00 (Reference)
Low income support 507 (23.8) 5375 (25.2) 0.92 (0.83, 1.02)
High income support 80 (3.8) 873 (4.1) 0.89 (0.71, 1.13)
Place of residencee
Urban 911 (42.8) 8837 (41.5) 1.00 (Reference)
Rural 1218 (57.2) 12460 (58.5) 0.95 (0.87, 1.04)
Oral contraceptive (OC) usef
None or light use (<12 prescriptions) 1620 (76.1) 16775 (78.8) 1.00 (Reference)
Heavy use (≥12) 509 (23.9) 4522 (21.2) 1.17 (1.05, 1.29)
Hormone therapy (HT) usef
None or light use (<12 prescriptions) 1503 (70.6) 15542 (73.0) 1.00 (Reference)
Heavy use (≥12) 626 (29.4) 5755 (27.0) 1.13 (1.02, 1.24)
OR, odds ratio(s); CI, confidence intervals.
aFrequency-matched on age in 5-year groups but not adjusted for the influence of other risk factors.
bFollow-up: number of years eligible to receive outpatient prescription drug benefits in Saskatchewan.
cMarital status: attributed to the marital state 6 years prior to index date.
dIncome support status: based on yearly demographic data and assigned to one of 3 categories based on the greatest proportion of time having received income
support: i.e., no income support, ≤50% of time receiving income support= low income support, and>50% of time receiving income support=high income support.
ePlace of residence: based on yearly demographic data and assigned based on the greatest proportion of time spent in a given residence state: i.e., ≤50% of time
in urban location (population>100,000)= rural residence status and >50% of time as urban=urban residence status.
fOC and HT use: defined as total number of prescriptions 2 or more years prior to index date. These drugs are typically dispensed as a 2-month supply; therefore,
in most cases, 12 prescriptions would correspond to a 2-year supply. All oral and injectable contraceptives were included as were all hormone therapy formulations
except vaginal creams and rings.
Percentages may not add up to 100% due to rounding.
of serotonin reuptake inhibition for the use of SSRI antidepres-
sants during the postulated etiologically relevant time period of
two or more years prior to index date. After adjustment for deter-
minants of breast cancer risk, exclusive users of high inhibitors
were not at increased risk for breast cancer compared with non-
users of SSRIs (OR= 1.01, CI= 0.88 – 1.17). Exclusive use of
lower inhibitors was also not associated with an increased risk
(OR= 0.91, CI= 0.67 – 1.25).
We did not observe an increase in breast cancer risk accord-
ing to duration of SSRI use, regardless of the degree of sero-
tonin reuptake inhibition (adjusted OR 1.15, CI= 0.89 – 1.50
and OR= 1.40, CI= 0.67 – 2.94 for exclusive users of ≥24 pre-
scriptions of high and lower inhibitors, respectively). However,
the number of long-term users (i.e., ≥24 prescriptions) was very
small (Table 3).
The risk of breast cancer associated with the use of SSRI antide-
pressants was independent of menopausal status, measured as age
at index, with no risk increase observed for either users of high
inhibitors (adjusted OR= 0.92, CI= 0.73–1.17 and OR= 1.07,
CI= 0.90–1.28 for women<55 years and≥55 years of age, respec-
tively; p= 0.24 for test of interaction) or lower inhibitors (adjusted
OR= 1.00, CI= 0.59–1.69 and OR= 0.87, CI= 0.59–1.28 for
women <55 years and ≥55 years of age respectively; p= 0.62 for
test of interaction) (Table 4).
Table 5 presents the risk estimates for breast cancer for exclu-
sive users of individual high inhibitors of serotonin reuptake (i.e.,
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Table 2 | Odds ratios for breast cancer according to the degree of serotonin reuptake inhibition of selective serotonin reuptake inhibitor (SSRI)
antidepressants.
SSRI categorya Cases
N =2129
(%) Controls
N =21297
(%) Unadjusted ORb
(95% CI)
Adjusted ORc
(95% CI)
n n
No used 1783 (83.8) 17908 (84.1) 1.00 (Reference) 1.00 (Reference)
Exclusive users of high inhibitorse 241 (11.3) 2381 (11.2) 1.02 (0.88, 1.17) 1.01 (0.88, 1.17)
Exclusive users of lower inhibitorse 44 (2.1) 482 (2.3) 0.92 (0.67, 1.25) 0.91 (0.67, 1.25)
Combined usersf 61 (2.9) 526 (2.5) 1.17 (0.89, 1.53) 1.17 (0.89, 1.53)
OR, odds ratio(s); CI, confidence intervals.
aSSRI (selective serotonin reuptake inhibitor) use anytime during follow-up 2 or more years prior to index date.
bMatched on age in 5-year age groups but unadjusted for the influence of other risk factors.
cAdjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
d“No use” (reference category) refers to women with no SSRI prescriptions dispensed 2 or more years prior to index date. Subjects may have filled prescription(s)
for SSRIs during the 2 years prior to index date which was not considered to be etiologically relevant.
e“Exclusive users” of high or lower inhibitors had 1 or more SSRI prescriptions dispensed from the specific sub-group of SSRIs being analyzed.
f“Combined users” refers to users of high and lower inhibitors. Cases and controls represent number of women within the “combined users” group with 1 or more
prescriptions dispensed for high inhibitors.
Percentages may not add up to 100% due to rounding.
Table 3 | Odds ratios for breast cancer according to the duration of selective serotonin reuptake inhibitor (SSRI) use.
No. of
SSRI prescriptionsa
Cases
N =2129
n
(%) Controls
N =21297
n
(%) Unadjusted ORb
(95% CI)
Adjusted ORc
(95% CI)
No used 1783 (83.8) 17908 (84.1) 1.00 (Reference) 1.00 (Reference)
Exclusive users of high inhibitorse
1–23 176 (8.3) 1818 (8.5) 0.97 (0.83, 1.14) 0.97 (0.82, 1.14)
≥24 65 (3.1) 563 (2.6) 1.16 (0.89, 1.51) 1.15 (0.89, 1.50)
Exclusive users of lower inhibitorse
1–23 36 (1.7) 425 (2.0) 0.85 (0.60, 1.20) 0.85 (0.60, 1.19)
≥24 8 (0.4) 57 (0.3) 1.41 (0.67, 2.96) 1.40 (0.67, 2.94)
Combined usersf
1–23 47 (2.2) 377 (1.8) 1.25 (0.92, 1.70) 1.26 (0.93, 1.72)
≥24 14 (0.7) 149 (0.7) 0.94 (0.54, 1.64) 0.94 (0.54, 1.64)
OR, odds ratio(s); CI, confidence intervals.
aSSRI (selective serotonin reuptake inhibitor) use anytime during follow-up 2 or more years prior to index date where the number of prescriptions dispensed approxi-
mates the number of months exposed.
bMatched on age in 5-year age groups but unadjusted for the influence of other risk factors.
cAdjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
d“No use” (reference category) refers to women with no SSRI prescriptions dispensed 2 or more years prior to index date. Subjects may have filled prescription(s)
for SSRIs during the 2 years prior to index date which was not considered to be etiologically relevant.
e“Exclusive users” of high or lower inhibitors had 1 or more SSRI prescriptions dispensed from the specific sub-group of SSRIs being analyzed.
f“Combined users” refers to users of high and lower inhibitors: subgroups represent number of prescriptions for high inhibitors only.
Percentages may not add up to 100% due to rounding.
paroxetine, sertraline, or fluoxetine) compared with non-users of
SSRI antidepressants. Short-term use of any of the high inhibitors
was not associated with a significantly increased risk of breast can-
cer. Although long-term use of sertraline was associated with an
elevated OR that was approaching statistical significance (adjusted
OR= 1.83, CI= 0.99–3.40), this analysis was based on only 12
exposed cases.
Findings were unaffected for all analyses after changing the
referent category from no prescriptions to ≤1 prescription.
DISCUSSION
In this large population-based case-control study, we found no
evidence of increased risk of breast cancer associated with the use
of high inhibitor SSRI antidepressants regardless of their duration
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Table 5 | Odds ratios for breast cancer according to total “exclusive use” of each individual high inhibitor antidepressant agent.
No. of
SSRI prescriptionsa
Casesb
N=2129
n
(%) Controlsb
N=21297
n
(%) Unadjusted ORc
(95% CI)
Adjusted ORd
(95% CI)
No usee 1783 (83.8) 17908 (84.1) 1.00 (Reference) 1.00 (Reference)
Paroxetine
1–23 69 (3.2) 629 (3.0) 1.10 (0.86, 1.42) 1.09 (0.85, 1.41)
≥24 15 (0.7) 131 (0.6) 1.15 (0.67, 1.97) 1.13 (0.66, 1.93)
Sertraline
1–23 37 (1.7) 295 (1.4) 1.26 (0.89, 1.78) 1.26 (0.89, 1.78)
≥24 12 (0.6) 66 (0.3) 1.83 (0.99, 3.39) 1.83 (0.99, 3.40)
Fluoxetine
1–23 48 (2.3) 613 (2.9) 0.79 (0.58, 1.06) 0.79 (0.58, 1.06)
≥24 14 (0.7) 167 (0.8) 0.84 (0.49, 1.46) 0.83 (0.48, 1.44)
OR, odds ratio(s); CI, confidence intervals.
aSSRI (selective serotonin reuptake inhibitor) use anytime during follow-up 2 or more years prior to index date where the number of prescriptions dispensed approxi-
mates the number of months exposed.
b151 cases and 1488 controls who were not exclusive users of one agent were not included in this analysis.
cMatched on age in 5-year age groups but unadjusted for the influence of other risk factors.
dAdjusted for age at index (years), marital status, income support status, residence status, and use of oral contraceptives and/or use of hormone therapy.
e“No use” (reference category) refers to women with no SSRI prescriptions dispensed 2 or more years prior to index date. Subjects may have filled prescription(s)
for SSRIs during the 2 years prior to index date which was not considered to be etiologically relevant.
Percentages may not add up to 100% due to rounding.
of use or menopausal status. While we cannot rule out the possi-
bility of a clinically important risk increase for long-term users of
sertraline (≥24 prescriptions), given the small number of exposed
cases (n= 12), the borderline statistical significance and the wide
confidence interval, these results need to be interpreted cautiously.
Our study is one of the largest studies published to date, and it
is the first to categorize SSRI exposure on the basis of the degree of
serotonin reuptake inhibition and thus, potential impact on pro-
lactin levels. As such, it is difficult to compare our results to those
of previous studies. Generally, our findings are consistent with
those studies that evaluated the relationship between SSRI use and
breast cancer risk (Coogan et al., 2005, 2008; Gonzalez-Perez and
Garcia Rodriguez, 2005; Chien et al., 2006; Fulton-Kehoe et al.,
2006; Ashbury et al., 2010; Cosgrove et al., 2011). In addition,
our results of no increased risk regardless of menopausal status
are consistent with previous studies that examined this relation-
ship including one that used the same age-based definition for
pre- and post-menopausal status as in our study (Gonzalez-Perez
and Garcia Rodriguez, 2005) and two other studies which defined
menopausal status based on menstrual history data obtained from
in-person interviews (Coogan et al., 2005, 2008).
While the point estimates for exclusive use of each of the
three individual high inhibitors (paroxetine, sertraline, and flu-
oxetine) appear to be different, any comparisons between results
for these three drugs are limited due to overlapping 95% con-
fidence intervals and small numbers of exposed cases (reflected
in the relatively wide confidence intervals). Other studies that
assessed risk of breast cancer according to duration of sertraline
use did not observe a statistically significant increase in risk asso-
ciated with longer durations of use (Coogan et al., 2005; Chien
et al., 2006; Fulton-Kehoe et al., 2006; Wernli et al., 2009; Ashbury
et al., 2010). However, similar to our analysis, these studies were
limited by a small number of long-term users of this agent and
corresponding wide confidence intervals. In addition, our findings
were consistent with other observational studies that specifically
assessed breast cancer risk associated with long-term use of parox-
etine (Gonzalez-Perez and Garcia Rodriguez, 2005; Haque et al.,
2005; Chien et al., 2006; Fulton-Kehoe et al., 2006; Ashbury et al.,
2010) and fluoxetine (Coogan et al., 2005; Gonzalez-Perez and
Garcia Rodriguez, 2005; Chien et al., 2006; Fulton-Kehoe et al.,
2006; Wernli et al., 2009; Ashbury et al., 2010) with the excep-
tion of Wernli et al. (2009) who reported a non-significant dose
response decrease in risk associated with increasing duration of
paroxetine use.
Our findings do not support a serotonin-mediated pathway
for the prolactin-breast cancer hypothesis even after taking into
account the extent of serotonin reuptake inhibition of individual
SSRIs and the duration of their use. Studies have reported varied
elevations in basal circulating prolactin measures with SSRI use –
often minimal to moderate increases in prolactin levels that are not
necessarily classified as hyperprolactinemia (Emiliano and Fudge,
2004; Molitch, 2005; Madhusoodanan et al., 2010; Trenque et al.,
2011). Therefore it is possible that chronic modest increases in
baseline circulating prolactin levels associated with the use of high
inhibitor SSRIs may not exceed the threshold necessary to promote
breast cancer development. Further, current evidence suggests that
the synthesis and secretion of prolactin is not solely regulated by
the pituitary gland, leading to questions about the carcinogenic
role of circulating prolactin (Clevenger et al., 2003; Fernandez
et al., 2010). Prolactin produced in breast epithelium independent
of circulating prolactin may regulate cell growth and differenti-
ation in breast tissue (Clevenger et al., 2003). Therefore higher
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levels of prolactin secreted by the pituitary gland secondary to an
SSRI-mediated increase in serotonin may not represent the most
relevant route of prolactin exposure at the tissue level in relation to
breast cancer etiology (Tworoger and Hankinson, 2008). Alterna-
tively, our reliance on the dissociation constant (Kd) for grouping
SSRIs as high and lower inhibitors may have introduced misclas-
sification of their effect on prolactin levels if the Kd measure was
not a good approximation of the prolactin-enhancing potential of
each SSRI.
The limitations of our study need to be considered. First, as
this study relied solely on administrative health and cancer reg-
istry data, the analysis did not account for some established risk
factors for breast cancer including family history, menstrual and
reproductive history. Studies have indicated that users of anti-
depressants as a class have higher BMI, more reproductive risk
factors, positive family history of breast cancer, increased likeli-
hood of a recent mammogram, and higher rates of HT or OC use
than non-users of antidepressants (Moorman et al., 2003; Chien
et al., 2006; Fulton-Kehoe et al., 2006). If these sources of con-
founding had influenced our results, our estimates would have
been spuriously elevated. As we found no association, residual
confounding cannot explain our results. Further, studies of physi-
cian prescribing practices have not reported associations with the
aforementioned risk factors (Olfson et al., 1998; Mojtabai, 2002;
Sleath and Shih, 2003). In addition, the analysis did not account
for use of other antidepressant medications such as tricyclic anti-
depressants (TCAs). However, most previous studies of TCAs have
reported no association with breast cancer risk (Chien et al., 2006;
Fulton-Kehoe et al., 2006; Wernli et al., 2009).
Also, the low prevalence of long-term use of SSRIs in our study
population resulted in underpowered analyses of the safety of
individual agents. However, our primary analysis of breast cancer
risk according to the degree of inhibition of serotonin reuptake,
a proxy for their impact on prolactin levels, was fully powered.
Also, given evidence suggesting that SSRIs are often prescribed for
relatively short periods of time (1–2 years) (Rosholm et al., 1997),
and that 50–80% of SSRI users discontinue their treatment after
less than 1 year (Meijer et al., 2004; Aikens et al., 2005) we postu-
late that designing studies with larger sample sizes of long-term
SSRI users may not be feasible due to the challenges of obtain-
ing a sufficient number of long-term users within the context
of past and current SSRI prescribing trends. Finally, our results
may not be generalizable to populations with a higher prevalence
of long-term use of SSRIs or longer duration of use as only 4%
of women in our study had received ≥24 prescriptions and the
median estimated duration of use was 7 months (inter quartile
range= 2–24 months).
In conclusion, we found no evidence of an increased risk of
breast cancer associated with the use of SSRIs even after account-
ing for their degree of serotonin reuptake inhibition and their
duration of use in women aged 28–79. Our results do not support
the serotonin-mediated pathway for the prolactin-breast cancer
hypothesis.
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